Headlines about Bellerophon Therapeutics (NASDAQ:BLPH) have been trending somewhat positive on Thursday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bellerophon Therapeutics earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.4079764603579 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several research firms have recently weighed in on BLPH. ValuEngine upgraded Bellerophon Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 8th. Zacks Investment Research upgraded Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research note on Monday, August 14th.

Bellerophon Therapeutics (NASDAQ:BLPH) traded down 1.32% during mid-day trading on Thursday, reaching $1.49. The company had a trading volume of 223,483 shares. The stock has a 50-day moving average of $1.33 and a 200 day moving average of $1.33. The company’s market capitalization is $52.91 million. Bellerophon Therapeutics has a 12-month low of $0.43 and a 12-month high of $1.98.

Bellerophon Therapeutics (NASDAQ:BLPH) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. On average, analysts expect that Bellerophon Therapeutics will post ($1.12) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Bellerophon Therapeutics (BLPH) Earns News Sentiment Rating of 0.07” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.watchlistnews.com/bellerophon-therapeutics-blph-earns-news-sentiment-rating-of-0-07/1642021.html.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Insider Buying and Selling by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.